With nearly 10 million baby boomers at risk for developing Alzheimer's disease, researchers are taking a closer look at a condition known as mild cognitive impairment. This is a state between the normal forgetfulness that comes with aging and the more pronounced thinking deficits of dementia. Mild cognitive impairment often progresses to Alzheimer's disease, but some people remain stable and others recover. New technology is improving the ability to determine who might fall into each category, reports the April 2008 issue of the Harvard Mental Health Letter. These developments are promising because they are occurring just as the first disease-modifying drugs for Alzheimer's have reached late-stage clinical testing.
One technology, fluorodeoxyglucose positron emission tomography (FDG-PET), measures blood glucose metabolism in the cerebral cortex. Diminished glucose uptake suggests that neurons are not as active. Clinicians can also measure brain volume changes with volumetric MRI to detect shrinkage, which is typical in Alzheimer's. These techniques are likely to prove most useful when combined with detection of newly discovered proteins believed to be the first signs of Alzheimer's.
If one of these technologies—or a combination—can reliably predict which people with cognitive impairment are likely to progress to Alzheimer's, scientists might be able to determine who should get the disease-modifying medications now in development. And they might be able to predict which healthy people are most likely to get mild cognitive impairment, and try to prevent it.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.